Joseph Francis Hokello
Bioprospecting for HIV-1 latency reversing agent (prostratin) from indigenous medicinal plants for latency reversal in HIV-1 subtypes A and D in Uganda (HIV-1_AD_LRA study)-PHASE-3
Joseph Francis Hokello

Context

Sub-Saharan Africa carries 68% of global HIV/AIDS prevalence. HAART prolongs life but cannot cure HIV due to latency, drug resistance, side effects, and high costs. Most latency reversal studies focus on subtype B, leaving subtypes A and D understudied despite their prevalence in Uganda.